Here’s why slashing insulin prices will actually save Big Pharma money

Enlarge / In this photo illustration, insulin pens manufactured by Novo Nordisk are displayed on March 14, 2023, in Miami, Florida.Getty | Joe Raedle

Heavyweight insulin maker Novo Nordisk said Tuesday that it will lower list prices for some of its insulin products by up to 75 percent by the end of the year, following in the footsteps of Eli Lilly, which made a similar announcement at the start of the month. Experts expect the third top insulin maker in the US, Sanofi, will follow suit.

The price cuts come after years of escalating public backlash to the companies’ steep price

→ Continue reading at Ars Technica

Related articles


Share article

Latest articles